Metastatic spine tumors (radionuclide vertebroplasty) radiopharmaceutical agent study by pre-clinical assessment of therapeutic potential

The preclinical studies of the functional suitability (therapeutic potential) of a new radiopharmaceutical intended for radionuclide verterboplasty were performed. In experiments on laboratory animals after 6 hours after filling the bone defect, the proportion of radiopharmaceutical retained was 99.89% on average. After 72 hours, the agent remained at the injection site by almost 100%, the accumulation of the agent in non-target organs and tissues was on the baseline, indicating a complete fixation of radiopharmaceutical in bone cement. The condition of animals treated with radiopharmaceutical varied from almost complete failure to the full recovery of limbs activity (equivalent use of both limbs). This indicates not only a decrease in the severity of pain, but also a stabilization of the bone structure with impaired integrity. In the group of untreated animals, impaired function was not restored, at the autopsy, spontaneous fractures of the tibia bone were found in the area of the bone defect. In vitro studies showed a slowdown in the formation of monolayer cells of the mammary adenocarcinoma in the culture flasks of the monolayer and their death on the 2^nd day after the start of incubation in the presence of radiopharmaceutical. The results of the studies indicate the functional suitability of the developed.

radiopharmaceutical, samarium-153, kyphoplasty, radionuclide vertebroplasty, polymethyl methacrylate, pharmacokinetics, preclinical studies, bone cement, malignant tumors